University of Leicester
nejmoa1600177.pdf (351.12 kB)

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

Download (351.12 kB)
journal contribution
posted on 2016-06-01, 11:55 authored by S. Yusuf, E. Lonn, P. Pais, J. Bosch, P. López-Jaramillo, J. Zhu, D. Xavier, A. Avezum, L. A. Leiter, L. S. Piegas, A. Parkhomenko, M. Keltai, K. Keltai, K. Sliwa, I. Chazova, R. J. Peters, C. Held, K. Yusoff, B. S. Lewis, P. Jansky, Kamlesh Khunti, William D. Toff, C. M. Reid, J. Varigos, J. L. Accini, R. McKelvie, J. Pogue, H. Jung, L. Liu, R. Diaz, A. Dans, G. Dagenais, HOPE-3 Investigators
BACKGROUND: Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. METHODS: In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or placebo. In the analyses reported here, we compared the 3180 participants assigned to combined therapy (with rosuvastatin and the two antihypertensive agents) with the 3168 participants assigned to dual placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included heart failure, cardiac arrest, or revascularization. The median follow-up was 5.6 years. RESULTS: The decrease in the LDL cholesterol level was 33.7 mg per deciliter (0.87 mmol per liter) greater in the combined-therapy group than in the dual-placebo group, and the decrease in systolic blood pressure was 6.2 mm Hg greater with combined therapy than with dual placebo. The first coprimary outcome occurred in 113 participants (3.6%) in the combined-therapy group and in 157 (5.0%) in the dual-placebo group (hazard ratio, 0.71; 95% confidence interval [CI], 0.56 to 0.90; P=0.005). The second coprimary outcome occurred in 136 participants (4.3%) and 187 participants (5.9%), respectively (hazard ratio, 0.72; 95% CI, 0.57 to 0.89; P=0.003). Muscle weakness and dizziness were more common in the combined-therapy group than in the dual-placebo group, but the overall rate of discontinuation of the trial regimen was similar in the two groups. CONCLUSIONS: The combination of rosuvastatin (10 mg per day), candesartan (16 mg per day), and hydrochlorothiazide (12.5 mg per day) was associated with a significantly lower rate of cardiovascular events than dual placebo among persons at intermediate risk who did not have cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; number, NCT00468923.).



New England Journal of Medicine, 2016, 374 (21), pp. 2032-2043

Author affiliation

/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cardiovascular Sciences


  • VoR (Version of Record)

Published in

New England Journal of Medicine


Massachusetts Medical Society



Copyright date


Available date


Publisher version


The file associated with this record is under embargo for 6 months from publication.



Usage metrics

    University of Leicester Publications


    No categories selected



    Ref. manager